An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT

BACKGROUND: Bendamustine is a bifunctional alkylating agent with unique properties that distinguish it from other agents in its class. Bendamustine is used as monotherapy or in combination with other agents to treat patients with non-Hodgkin lymphoma (nhl) and chronic lymphocytic leukemia (cll). MET...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Curr Oncol
Hlavní autoři: Kouroukis, C.T., Crump, M., MacDonald, D., Larouche, J.F., Stewart, D.A., Johnston, J., Sauvageau, S., Beausoleil, E., Sage, P., Dubois, S.G., Christofides, A., Di Clemente, S., Sehn, L.
Médium: Artigo
Jazyk:Inglês
Vydáno: Multimed Inc. 2015
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4530811/
https://ncbi.nlm.nih.gov/pubmed/26300664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.22.2431
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky